Sandoz gains exclusive commercialization rights to biosimilar SB17 ustekinumab in Samsung deal

Sandoz, a global leader in generic and biosimilar medicines, announced that it has entered into a development and commercialization agreement with Samsung Bioepis.

The agreement provides Sandoz with the exclusive rights to commercialize the biosimilar SB17 ustekinumab in the US, Canada, EEA, Switzerland, and UK. Other specific terms of the agreement are confidential. Ustekinumab is a fully human monoclonal antibody to interleukin (IL)-12/23, approved for treatment of plaque psoriasis, psoriatic arthritis, Crohn´s disease and ulcerative colitis. The reference medicine Stelara (ustekinumab) is a monoclonal antibody medication to interleukin (IL)-12/23 for the treatment of autoimmune disorders including Crohn’s disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis.

“This deal represents another major step to reinforce our high-value biosimilar pipeline, in line with our plans to become a standalone global leader,” says Sandoz CEO Richard Saynor. “It will further strengthen our immunology patient offering and means we now have five potential high-value upcoming biosimilar launches over the next few years.”

For Sandoz, which is due to become an independent company from Novartis early next month, the transaction means more investment in the growing market of biosimilars, which are lower-cost copies of complex biotech drugs that have lost patent protection.

 Visit our Biosimilars conference – https://virtueinsight.com/event/biosimilars-congregation-2023/